The entire transaction, legally disclosed in a filing with Securities & Exchange Commission, was a total of $64,500.
Piper Jaffray Cos. has also increased Amsurg’s target price from $36 to $42. Analysts with Deutsche Bank have raised their target price for the company from $39 to $45.
More Articles on Transactions and Valuation Issues:
Medical Facilities Corporation Announces October Dividend
What to Consider Before Selling an ASC
Key Observations on ASC Transactions in 2013
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.